We used the Salmonella typhi galactose epimerase (galE) mutant strain Ty2la, shown to be a safe, effective, living, attenuated oral typhoid vaccine, as a recipient for a recombinant plasmid containing the gene for production of the nontoxic B subunit of the heat-labile enterotoxin of Escherichia coli. The S. typhi derivative, strain SE12, produced heat-labile enterotoxin subunit B that was structurally and immunologically indistinguishable from heat-labile enterotoxin subunit B produced by strains of E. coli harboring the same plasmid. Tests in mice and guinea pigs showed that strain SE12 was safe when given orally and was capable of inducing a significant antitoxic antibody response when injected parenterally. Moreover, it retained the galactose sensitivity of the parent strain, preserving its utility as a typhoid vaccine. This strain may prove to be a useful live oral bivalent vaccine strain for typhoid fever and cholera-E. coli-related diarrheas.
The extensive diarrhea of cholera results from the elaboration of a potent exo-enterotoxin which causes the activation of adenylate cyclase and a subsequent increase in intracellular levels of cyclic AMP. This enterotoxin (choleragen) is an 84,000-dalton polymeric protein composed of two major, noncovalently associated, immunologically distinct subunits designated A and B (11) . Of these, the 56,000-dalton B subunit is responsible for the binding of the toxin to the host cell receptor (12) . The B subunit is nontoxic and appears to be the immunodominant moiety of the holotoxin (17, 28, 35) .
A variety of cholera vaccines have been developed since the identification of the causative organism by Koch (recently reviewed by Levine et al. [28] ), the most widely used being parenterally administered killed whole-cell vaccines. Unfortunately, these vaccines give rise to only limited protection of short duration (10) . A number of toxoid vaccines have been proposed, but have never been proven to be safe or effective. Formalin toxoid, although capable of eliciting antitoxin antibodies, reverted to toxicity (33) , whereas glutaraldehyde toxoid was stable but poorly antigenic (9) . Subunit toxoid vaccines (B subunit toxoid) have also been proposed, and Svennerholm et al. (38) have found increasing titers of local intestinal secretory immunoglobulin A antitoxin after oral or intramuscular immunization with cholera toxin subunit B (CT-B). In the most recent efforts to develop an effective immunoprophylactic for cholera, researchers have used mutagenesis (1, 13, 18) or recombinant DNA technology (19, 20, 30) to construct strains of Vibrio cholerae genetically incapable of producing the toxic A fragment of the enterotoxin. Some of these strains, when studied in human volunteers, have provided a degree of protection against challenge with V. cholerae, with an overall reduction in the occurrence of diarrhea (27) .
A number of enteric pathogens, principally enterotoxigenic Escherica coli, have been shown to produce a plasmidmediated heat-labile enterotoxin (LT) which is immunologically related to choleragen (3, 4) . The role of antitoxic immunity in protection against diarrhea caused by these organisms has never been clearly established. Levine et al. (29) have shown that in volunteers, previous disease caused by LT-producing E. coli does not protect against challenge * Corresponding author.
with a heterologous LT-producing strain; and Svennerholm and Ahren (37) have shown that passive protection in rabbits is improved when antibacterial antibodies are included with antitoxic antibodies. Other studies have shown that immunization with LT or the B subunit of LT (LT-B) can stimulate production of mucosal secretory antitoxic immunoglobulin A (23) and that these antitoxic antibodies are protective (22) (23) (24) . Moreover, Klipstein et al. (25) have shown that immunization with LT-B raises an antitoxin response that provides protection against LT or CT, whereas immunization with CT-B induces much weaker cross-protection. These results indicate that LT-B may be a more effective immunoprophylactic against cholera and enterotoxigenic E. coli than CT-B.
It is against this background that we constructed a potential live oral vaccine for cholera-and E. coli-related diarrhea. As a vehicle, we used the galactose epimeraseless (galE) mutant of Salmonella typhi (15) , which has been shown to be a safe, highly effective, live, oral vaccine for typhoid fever (16, 42) . This strain, S. typhi Ty2la, has been used by Formal et al. (14) to construct a potential bivalent dysenterytyphoid vaccine, whose safety and antigenicity have recently been demonstrated in volunteers (40 (36) . Rat ligated ileal loops were treated as previously described (21) . Briefly, a graded toxin dose was instilled into a single 10-cm ligated loop of distal ileum for 18 h. The volume of the loop (in microliters) was compared with the length (in centimeters). and a ratio was determined. Each data point was determined by testing three rats.
Galactose-induced cell lysis. The sensitivity of S. typlhi Ty2la and SE12 to lysis by galactose was determined by inoculating each strain into ML medium (10 g with and without 0.1% galactose. Cell lysis was followed by monitoring the optical density at 650 nm during a 10-h growth period at 37°C.
Persistence in mouse tissues. Studies to determine the persistence of S. typhi Ty2la and the derivative strain SE12 in mouse tissues were conducted essentially as described by Formal et al. (14) . Each strain was grown in brain heart infusion broth (Difco) containing 0.1% galactose. washed in sterile normal saline, and suspended in saline to ca. 5 x 107 CFU/ml. Groups of female outbred CD-1 mice (Charles River Breeding Laboratories, Inc., Wilmington, Mass.) were injected intraperitoneally (i.p.) with 0.5 ml of either strain. brain heart infusion broth containing 0.1% galac-
The cloned LT-B DNA fragment was recloned from shed in sterile normal saline, and suspended in pDF87 into the single HindlIl site of the M13-derived 3 x 109 CFU/ml. Five female Hartley albino guinea cloning vector pUC8 (41) . Plasmid pDF87 was cut with rles River Breeding Laboratories), each weighing Hindlll, and the 0.8-kb fragment which codes for production 50 g, were inoculated orally with 1 ml each and of LT-B was separated by electrophoresis through lowfor signs of diarrhea for 14 days. clone, designated JM83(pJC217), was selected for further formed as previously described (6) . Samples to be study. Plasmid DNA was purified from this clone, and when were serially diluted in phosphate-buffered saline recut with HindlIl, it contained only two fragments: one -0.05% Tween 20. Titer was defined as the recipro-corresponding to the 2.7-kb cloning vector, pUC8, and one dilution giving an absorbance value of 1.0 at 410 of 0.8 kb coding for production of LT-B (Fig. 1 The S. tvphi transformant SE12 was examined for the presence of plasmid pJC217. Plasmid DNA was prepared from the transformant and examined by agarose gel electrophoresis. Strain SE12 (Fig. ID) contained plasmid pJC217 , which, when cut with HindIll, yielded the same two 2.7-and 0.8-kb fragments seen with pJC217 (Fig. 1B) .
Characterization of LT-B production by S. typhi derivative strain SE12. A major consideration in the construction of a potential bivalent vaccine was that the LT-B produced by the S. tvphi be structurally and immunologically identical to the LT-B produced by E. coli. After purification by agarose affinity chromatography, LT-B from strain SE12 was examined by SDS-PAGE, ELISA, and Ouchterlony analysis. The SE12 LT-B ( Fig. 2A) was indistinguishable from the LT-B produced by E. coli JM83(pJC217) (Fig. 2B) in SDS-PAGE.
Both preparations contained only the single band representing LT-B. As expected, neither preparation contained a band corresponding to LT-A (Fig. 2C) . When assayed by ELISA against antiserum to LT-B, the two preparations were immunologically identical (Fig. 3) , an observation confirmed by immunodiffusion analysis (data not shown).
The biological activity of LT-B produced by strain SE12 was tested in the rat ligated ileal loop assay. LT produced a positive response in this assay with as little as 1 pLg of material, whereas LT-B purified from E. coli JM83(pJC217) or from S. typlhi SE12 had no effect at doses as high as 100 jig (Table 2) .
Distribution of LT-B produced by S. typhi SE12. When produced by E. coli, LT is found to be principally cell associated: more than 95% was found within the cell (5). This was also found to be true for several other genera of Enterobacteriacette containing Ent plasmids (32) . Neill derivative, and the effect that incorporation of galactose into the culture medium would have on production of LT-B.
Approximately 50%c of LT-B produced by strain SE12 remained cell associated, with an equal amount being released from the cell (Table 3) . When galactose was added to the culture medium, the percentage of extracellular LT-B increased to 89%, probably a reflection of galactose-induced cell lysis (see below).
Galactose-induced cell lysis. The safety of S. typhi TY21a as a vaccine is due in part to the avirulence resulting from the galE mutation. A prerequisite of that avirulence is sensitivity to galactose: strain Ty2la completely lysed after the addition of galactose to the culture medium (15) . To be an effective bivalent vaccine candidate, an S. tVphii Ty2la derivative producing LT-B would need to retain that sensitivity to galactose. The growth curves for S. typhi SE12, in the presence or absence of 0.1% galactose, are shown in Fig. 4 showing development of significant mucosal antitoxic responses after oral administration of any of these A-B' mutants of V. cholerae. Unlike V. cholerae, which is noninvasive and principally colonizes the proximal small bowel, S. tvphi is invasive, affects the distal small bowel, and enters the lymphoid tissues of the host. Theoretically, use of a live bacterium (S. typhi) to deliver a toxoid antigen directly to the lymphoid tissues should be more effective at inducing antitoxic antibodies than use of an organism (V. (Iholerae) which distributes the same toxoid antigen randomly over the intestinal epithelial surface. Formal et al. (14) have suggested that the stimulation of antibody-forming cells in the lamina propria may contribute to the protection provided by the galE S. typhi Ty2la (15, 16, 42) or its derivative containing the form I antigen plasmid of Shigella sonnei (14) . It therefore seems possible to use a similar approach for the delivery of toxoid antigens directly to the lymphoid tissues to stimulate a protective mucosal antitoxin response effective against cholera and other immunologically related enterotoxic manifestations.
In this study, we used the S. typhi galE mutant vaccine strain Ty2la as a recipient for a recombinant plasmid containing the gene for production of the LT-B of E. oli. The S. typhi derivative strain SE12 was shown to contain the 3.5-kb LT-B plasmid and produced LT-B that was structurally and immunologically indistinguishable from the LT-B produced by strains of E. coli harboring the same plasmid and that possessed no demonstrable biological activity. The derivative strain was rapidly cleared after intraperitoneal injection into mice, caused no diarrhea or other manifestations when inoculated orally into guinea pigs, and retained the galactose sensitivity characteristic of the parent strain S. typhi Ty2la. More importantly, mice injected intraperitoneally with SE12 developed a significant antibody response which could be specifically boosted with a subsequent injection of either viable organisms or purified LT-B. Since S. typhi is a pathogen only of humans and a few primates, the ability of this strain to induce a specific mucosal antitoxic response will be tested in a forthcoming study.
